Innovent Constructing Biologic Facility in Suzhou

November 1, 2012 -- Innovent Biologics, a Suzhou company formed last year, is building a biotech plant in BioBay. The company has two aims: it intends to in-license biotech drugs for the China market, and it also wants to provide contract manufacturing services to other companies. The company is led by an international management team of experienced biotech executives. With $30 million in startup capital from Fidelity, Lilly Ventures and Suzhou BioBay, Innovent has instant credibility. More details....